Immunotherapy company Batu Biologics Inc revealed on Friday the election of Thomas Ichim as its president and chief executive officer.
In the new positions, Dr Ichim replaces the company's outgoing CEO Samuel Wagner, who has moved on to other opportunities.
Dr Ichim will lead the immuno-oncology company in developing the US FDA cleared ValloVax IND, an allogeneic cellular vaccine that specifically programmes the immune system to kill the blood vessels that feed. Its efficacy has been demonstrated in animal models and early clinical safety has been published in a case series.
Previously, Dr Ichim was employed with Medistem, where he successfully took an angiogenesis based cell therapy from concept to exit in the field of angiogenesis inhibition, added the company's chairman Dr Alan Lewis.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine